Loading clinical trials...
Loading clinical trials...
An Open-Label, Dose-Response Study of CM4620 Injectable Emulsion (CM4620-IE) in Patients With Acute Pancreatitis and Accompanying Systemic Inflammatory Response Syndrome (SIRS)
Conditions
Interventions
CM4620 Injectable Emulsion (Low Dose)
CM4620 Injectable Emulsion (High Dose)
Locations
9
United States
Detroit Receiving Hospital (Wayne State)
Detroit, Michigan, United States
Henry Ford Hospital
Detroit, Michigan, United States
Sinai-Grace Hospital (Wayne State)
Detroit, Michigan, United States
Hennepin County Medical Center
Minneapolis, Minnesota, United States
Regions Hospital
Saint Paul, Minnesota, United States
Washington University
St Louis, Missouri, United States
Start Date
March 12, 2018
Primary Completion Date
February 14, 2019
Completion Date
April 30, 2019
Last Updated
March 30, 2026
NCT04195347
NCT06651580
NCT06553651
NCT07395778
NCT07171112
NCT03684278
Lead Sponsor
CalciMedica, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions